Results 31 to 40 of about 5,232 (145)

Effective Use of Topical Sucralfate in the Conservative Management of Expanded Gastrostomy Tract Reduction

JPGN Reports, Volume 2, Issue 3, August 2021., 2021
Sucralfate is a common medication used to treat duodenal ulcers, gastric ulcers, and gastritis. The off‐label use of topical sucralfate has been described in the literature to induce wound healing in epithelial injury. Yet, current literature lacks clinical depictions in the application of sucralfate to treat a common gastrostomy tube complication ...
Hengqi Betty Zheng, Mary Len, Nicole Pattamanuch   +2 more
wiley   +1 more source

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease [PDF]

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, efficacy, and safety of the first nebulized long-acting muscarinic antagonist (LAMA), glycopyrrolate (GLY)/eFlow closed system (CS) nebulizer, approved for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Xiaoli Niu, Victoria Divino, Sanjay Sharma, Mitch Dekoven, Vamshi Ruthwik Anupindi, Carole Dembek   +5 more
openaire   +5 more sources

Laser plume containment during flexible transnasal laryngoscopy

Laryngoscope Investigative Otolaryngology, Volume 6, Issue 2, Page 234-243, April 2021., 2021
Abstract Objective To evaluate a negative pressure microenvironment designed to contain laser plume during flexible transnasal laryngoscopy. Methods The Negative Pressure Face Shield (NPFS) was previously reported as well tolerated with initial use on 30 patients.
Henry T. Hoffman, Jarrett E. Walsh, Alessandra Pratt, Robert M. Miller, Adam Schwalje, Helen R. Stegall, Matt Nonnenmann   +6 more
wiley   +1 more source

Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors. [PDF]

Chronic Obstr Pulm Dis, 2018
Purpose: The purpose of this study was to assess the effect of pre-existing cardiovascular (CV) risk factors on the efficacy and safety of nebulized glycopyrrolate (GLY) in patients with chronic obstructive pulmonary disease (COPD). Methods: A total of 2379 patients from 3 phase III studies (12-week, placebo-controlled Glycopyrrolate for Obstructive ...
Ferguson GT, Tosiello R, Sanjar S, Goodin T.   +3 more
europepmc   +4 more sources

Airway management of angioedema patients during the COVID‐19 pandemic

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 6, Issue S1, Page S36-S39, November 2020., 2020
Importance The COVID‐19 pandemic is characterized by high transmissibility from patients with prolonged minimally‐ or asymptomatic periods, with a particularly increased risk of spread during aerosol‐generating procedures, including endotracheal intubation. Observations All patients presenting with upper airway obstruction due to angioedema during this
Tiffany N. Chao, Joshua H. Atkins, Zaffer Qasim, James J. Kearney, Natasha Mirza, Christopher H. Rassekh   +5 more
wiley   +1 more source

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]

International Journal of COPD, 2021
Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S. Int J Chron Obstruct Pulmon Dis. 2020;15:995–1004. The authors have advised there is an error in Figure 4B on page 1000.
Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S   +3 more
doaj  

Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials.

, 2021
PURPOSE OF REVIEW: Although experimental evidence supports the use of nebulized antibiotics in ventilator-associated pneumonia (VAP), two recent multicenter randomized controlled trials (RCTs) have failed to demonstrate any benefit in VAP caused by Gram ...
Rello, Jordi, Zhu, Yinggang, Monsel, Antoine, Laterre, Pierre-François, Torres, Antoni, Rouby, Jean-Jacques, Pugin, Jerome, European Investigators Network for Nebulized Antibiotics in Ventilator-associated Pneumonia (ENAVAP)   +7 more
core   +1 more source

Nebulized antibiotics for healthcare- and ventilator-associated pneumonia

, 2022
Global emergence of multidrug-resistant and extensive drug-resistant gram-negative bacteria has increased the risk of treatment failure, especially for healthcare- or ventilator-associated pneumonia (HAP/VAP).
Bouglé, Adrien, Rello, Jordi, Dhanani, Jayesh, Arvaniti, Kostoula, Blot, Stijn, Mimoz, Olivier, Sole-Lleonart, Candela, On Behalf of the European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP), [missing], Rouby, Jean-Jacques, Boisson, Matthieu   +9 more
core   +1 more source

Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives

Clinical Pharmacology &Therapeutics, Volume 106, Issue 6, Page 1222-1235, December 2019., 2019
Chronic obstructive pulmonary disease (COPD) remains a leading cause of death worldwide, yet only one new drug class has been approved in the last decade. However, resurgence in COPD treatment has been recently fueled by a greater understanding of the pathophysiology and natural history of the disease, as well as a growing prevalence and an aging ...
Aernout van Haarst, Lorcan McGarvey, Sabina Paglialunga   +2 more
wiley   +1 more source

Acute Awake Fiberoptic Intubation in the ICU in a Patient with Limited Mouth Opening and Hypoxemic Acute Respiratory Failure

Case Reports in Anesthesiology, Volume 2019, Issue 1, 2019., 2019
The incidence and survival of patients with head‐and‐neck cancer have been on the increase for decades. Following surgery or radiation therapy, complications such as difficult airways may evolve. These difficult airways may be unique and not manageable with conventional intubation methods as well as video laryngoscopes.
Kjartan E. Hannig, Rasmus W. Hauritz, Christian Jessen, Anders M. Grejs, Pavel Michalek   +4 more
wiley   +1 more source